Janssen Biotech Inc.

11/20/2023 | Press release | Distributed by Public on 11/20/2023 08:17

Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of RYBREVANT ® (amivantamab-vmjw) Plus Chemotherapy for the Treatment of Patients with[...]